Introduction
Positive transcription elongation factor b (P-TEFb) facilitates transcription elongation through phosphorylation of RNA pol II carboxyl-terminal domain (CTD). The active core of P-TEFb comprises cyclin-dependent kinase 9 (cdk9) and a C-type regulatory cyclin (cyclin T1, T2, K) (reviewed in (1)).
Cdk9 exist in mammalian cells in two isoforms, p42 cdk9 and p55 cdk9 with a tissue-specific expression pattern, responding to different signals (2) . Both isoforms phosphorylate Ser-2 of multiple heptapeptide repeats of CTD RNA pol II releasing the repression action of the DRB sensitivity-inducing factor (DSIF) and the negative elongation factor (NELF). P-TEFb is required not only as a basic transcription elongation factor, but it is also recruited by some transcription factors to activate transcriptional elongation from specific promoters. For example, the requirement of cyclin T1/cdk9 complex by the HIV-1 Tat protein to efficiently elongate the viral RNA has been extensively studied (3, 4) . Other transcription factors targeting 3 P-TEFb to the promoters of its target genes include MyoD (5) , c-Myc (6) , STAT3 (7) , NFκB (8) , androgen receptor (AR) (9) , and the aryl hydrocarbon receptor (10) , implicating cyclin T/cdk9 complex in the regulation of cellular processes such as heat-shock response, antigen presentation and processing, apoptosis, muscle cell differentiation, cell growth, or cell proliferation. Moreover, interaction of c-Myc with cyclin T1 and cdk9 results in efficient transcription of c-Myc target genes, and inhibition of cdk9 with DRB, at a concentration that is not inhibiting the general transcription process, results in the block of c-Myc induced proliferation and apoptosis (6) . Of particular interest is the participation of P-TEFb in differentiation processes. Interaction of cdk9 with MyoD results in increased differentiation of muscle cells. Interestingly, MyoD interacted with, and was phosphorylated by cyclin T2/cdk9 complex, whereas c-Myc and NFκB were shown to recruit the cdk9/cyclin T1 complex (5) . Hence, the specificity of the interaction might be dictated by the cyclin T component of the P-TEFb complex (1) . Cdk9 is also required for the monocyte differentiation program. In these cells, cyclin T1 is highly induced upon stimulation with PMA (11) . High levels of expression of cyclin T1 and T2, as well as cdk9 in differentiated tissues suggest the participation of P-TEFb in the activation or maintenance of specific differentiation processes (12, 13) .
Interestingly, white adipose tissue showed very high level of expression of cyclin T1 (12) . All these studies prompted us to investigate the role of P-TEFb in the adipocyte differentiation process.
Adipogenesis is a particular system, which involves two major events: preadipocyte proliferation and adipocyte differentiation. Upon reaching confluence, proliferative preadipocytes become growth arrested by contact inhibition. Those cells re-enter cell cycle after hormonal induction, arrest proliferation again and undergo terminal adipocyte differentiation. This last stage is characterized by the coordinated expression of specific genes that will finally determine the specific adipocyte phenotype of the cells. The major regulator of terminal adipocyte differentiation is the peroxisome proliferator-activated receptor gamma (PPARγ (reviewed in (14, 15) ), which is induced during the initial phases of these terminal stages of adipogenesis by C/EBPβ and δ, as well as by E2F1 (16) PPARγ, upon activation by either fatty acid derivatives or antidiabetic thiazolidinediones, drives the expression of several adipocyte-specific genes, such as the fatty acid binding protein (aP2) thus transforming the cell into the characteristic lipid rich adipocyte (17) . Subsequent studies have demonstrated that ectopic expression of PPARγ further induces 4 adipocyte differentiation (18) . This pivotal role of PPARγ in adipocyte differentiation is also highlighted by the phenotype observed in humans with mutations in the PPARγ gene and by PPARγ deficient mice which are essentially devoid of white adipose tissue (19) .
In this study we show that cyclin T1, T2, and cdk9 are expressed in adipocytes. Furthermore, cdk9 activity is increased during adipocyte differentiation. We show that inhibition of cdk9 activity impairs adipogenesis, whereas ectopically expressed cdk9 is highly adipogenic in 3T3-L1 cells. The adipogenic effects of cdk9 are mediated by the induction of PPARγ transcriptional activity through direct phosphorylation. Finally, we show that PPARγ is complexed with P-TEFb on promoters of PPARγ target genes.
Results

P-TEFb is expressed and active in differentiated adipocytes
While evaluating the participation of the P-TEFb complex in adipocyte differentiation we found that cdk9 was expressed at all stages of differentiation of 3T3-L1 preadipocytes, both at the RNA and protein level ( Fig.1A-B ). Interestingly, western blot analysis as well as RNA quantification showed that the expression of p55 cdk9 protein isoform was strongly increased during adipocyte differentiation, whereas p42 cdk9 expression was unchanged ( Fig.1A-B ). No differences in the expression of cyclin T1 or cyclin T2 were observed (data not shown). aP2 mRNA expression was quantified as a marker of differentiation (Fig. 1C ).
To further study the expression of P-TEFb during adipogenesis, immunofluorescence analyses were performed. During early stages of differentiation of 3T3-L1 cells cdk9 was evenly distributed between the cytoplasm and the nucleus ( Fig. 1D ; days 0 and 1). Starting at day 3, cdk9 expression became more prominent in the nuclear compartment ( Fig. 1D ). Strikingly, at this stage of differentiation coexpression of cdk9 with PPARγ in the nucleus of differentiating cells could be observed ( Fig. 1D ; days 3,8). Similar results were observed when the expression of cyclins T1 and T2 were analyzed (supplemental Fig. 1 ). Furthermore, immunoprecipitated cdk9 from differentiated adipocytes was able to phosphorylate purified recombinant RNA pol II CTD, showing a gradual increase in cdk9 activity as, as measured by the level of RNA pol II CTD phosphorylation, indicating that cdk9 was indeed active in adipocytes (Fig. 1E ). This 5 was consistent with the increase in nuclear localization of cdk9 at the same stages of adipocyte differentiation ( Fig. 1D) .
These results suggested a role of P-TEFb in adipose tissue biology and differentiation.
DRB inhibition of cdk9 results in impaired clonal expansion and terminal adipocyte differentiation
To further assess the role of cdk9 in the differentiation of 3T3-L1 cells, cdk9 activity was inhibited using 5,6-dichloro-1-β-ribofuranosyl-benzimidazole (DRB). 3T3-L1 cells treated with either vehicle or DRB were compared for their ability to differentiate into adipocytes. After 8 days in differentiation media, normal lipid accumulation was observed in control cells whereas a dose-dependent decrease in lipid accumulation was observed in cells treated with DRB, as showed by Oil Red O staining ( Fig. 2A ).
Quantitative RT-PCR performed on differentiated 3T3-L1 cells confirmed a DRB dose-dependent decrease in expression of the PPARγ target gene aP2, which is a marker of adipocytes ( Fig. 2B ). 3T3-L1 preadipocytes re-enter cell cycle after hormonal induction of differentiation (the clonal expansion phase).
Since this is a required event of these cells before terminal differentiation into adipocytes, we next explored the hypothesis that cdk9 participates in adipogenesis through the control of cell cycle during the clonal expansion phase. A decrease in cell proliferation during the clonal expansion phase (days 1 and 2) was observed, as measured by BrdU incorporation assays, in cells treated with DRB compared to cells treated with vehicle ( Fig. 2C ). This indicated that inhibition of cdk9 by DRB suppressed, at least in part the clonal expansion phase of adipogenesis. Furthermore, the decrease in cyclin B1 mRNA expression at day 1 of differentiation in cells treated with DRB suggested that cdk9 could participate in the control of the G2/M transition ( Fig. 2D ). No differences in the expression of cyclin D1 or DHFR were observed at this stage, whereas a significant reduction in the expression of these genes was observed at day 2 of differentiation ( Fig. 2D ). To further elucidate whether the role of cdk9 was limited to the regulation of the clonal expansion phase of adipocyte differentiation, cdk9 activity was inhibited starting at day 3 of differentiation. At this particular stage 3T3-L1 cells are quiescent and have already gone through the clonal expansion phase (data not shown). Five days after (day 8) treatment, oil-red-O staining indicated an inhibitory dose-dependent effect of DRB in lipid accumulation ( Fig. 2E) . A dose-dependent decrease in 6 aP2 mRNA expression in DRB treated cells further demonstrated inhibition of adipogenesis ( Fig. 2F ).
These results suggested that cdk9 has a dual role in adipogenesis, i.e. a first role promoting the clonal expansion phase, and a second role promoting terminal differentiation.
Impaired expression of cdk9 modulates adipogenesis
The observed effects of DRB in adipogenesis could be the result of the inhibition of kinases other than cdk9. To prove the implication of cdk9, a 3T3-L1 cell line overexpressing a dominant negative, kinase dead cdk9 (DNcdk9) was created. Oil-red-o staining indicated that after 8 days in differentiation medium, these cells lost their capacity to differentiate into adipocytes, compared to cells expressing an empty vector ( Fig. 3A ). Overexpression of DNcdk9 was assessed by PCR assay ( 
Cdk9 increases PPARγ γ γ γ activity
Since P-TEFb has an impact on adipogenesis we tested whether these effects could be mediated by PPARγ, which is the master regulator of adipocyte differentiation. To analyse the influence of cdk9 on Furthermore, the presence of acetylated histone H4 on the PPARγ binding site of the aP2 promoter suggests that, in the presence of cdk9, this promoter is active. These results suggest that P-TEFb's stimulatory role during adipogenesis is likely the result of its ability to modulate PPARγ activity.
Cdk9 physically interacts with PPARγ γ γ γ
To test whether the induction of PPARγ activity in the presence of P-TEFb is the consequence of a direct interaction between PPARγ and cdk9, nuclear extracts from COS cells transfected with cdk9 and PPARγ 8 expression vectors were immunoprecipitated with cdk9, or irrelevant antibodies. PPARγ protein could be detected in cdk9 immunoprecipitates as assessed by western-blot analysis ( Fig. 5A ), suggesting that a
PPARγ-cdk9 complex is present in these cells. To identify the PPARγ domain responsible for the interaction, GST-PPARγ fusion proteins containing different PPARγ domains were incubated with invitro translated 35 S-radiolabeled cdk9 (Fig. 5B ). Interestingly we found that cdk9 bind to both the A/B and DE domains of PPARγ ( Fig. 5C-D) . In particular, cdk9 bound to a region from aa 1-72 and 292-399. Same results were observed when cyclin T1 or T2 were used instead of cdk9 (data not shown). These results further demonstrated a direct interaction between cdk9 and PPARγ.
Cdk9 phosphorylates PPARγ γ γ γ
Cdk9 is a cyclin dependent kinase that modulates the activity of its substrates through phosphorylation.
We wanted therefore to test whether modulation of PPARγ activity implicated its phosphorylation by cdk9. Overexpression of cdk9 and cyclin T in Saos cells, resulted in the accumulation of the phosphorylated form of PPARγ as assessed by western blot analysis ( Fig. 6A ), suggesting that PPARγ could be a target for cdk9. Moreover, immunoprecipitated cdk9 from 293 cells was able to in vitro phosphorylate purified full length GST-PPARγ, whereas neither GST alone or GST-PPARγ LBD, which contains the PPARγ ligand binding domain were phosphorylated by cdk9 ( Fig. 6B ). In contrast, GST-PPARγ A/B, which contains the PPARγ A/B domain was indeed phosphorylated by cdk9 ( Fig. 6B ). The PPARγ A/B domain contains S112 which has been shown to be phosphorylated by other serine-threonine kinases, such as cdk7. To investigate whether this residue was the target for cdk9, S112 was replaced by an alanine (S112A). GST-PPARγ A/B-S112 was not phosphorylated by cdk9 ( Fig. 6B , right panel). These results demonstrate that cdk9 phosphorylates PPARγ at S112. To further elucidate how PPARγ phosphorylation could influence its transcriptional activity, we correlated the expression of the PPARγ target gene aP2 with the phosphorylation status of PPARγ. As expected, 3T3-L1 adipocytes treated with rosiglitazone increased the expression of aP2 (Fig. 6C ). This effect was blunted by the addition of the PPARγ antagonist GW9662 (Fig. 6B ). Strikingly, maximal aP2 induction correlated with the accumulation of the PPARγ phosphorylated forms (Fig. 6D) . Similarly, the observed decrease in aP2 9 expression upon incubation with GW9662 correlated with a switch to non-phosphorylated PPARγ (Fig.   6D ). Furthermore, incubation of 3T3-L1 adipocytes with the cdk9 inhibitor DRB resulted in a decrease in aP2 mRNA expression to the levels observed in cells treated with the PPARγ antagonist GW9662 ( Fig.6E ). Interestingly, PPARγ phosphorylation was inhibited when cells were incubated with DRB ( Fig.   6F ). Quantification of the relative intensity of the bands demonstrated that the observed reduction in PPARγ phosphorylation levels was similar to what observed using the PPARγ antagonist GW9662 ( Fig.   6D and 6F). Over all these results suggested that phosphorylation by cdk9 increases PPARγ activity.
Further supporting this hypothesis was the observation that, in differentiated adipocytes, phosphorylated
PPARγ is complexed with the aP2 promoter as demonstrated by ChIP assays (Fig. 6G ). Coincident with phospho-PPARγ is the presence of cdk9 and acetylated histone H4 in the aP2 PPRE, indicating that under these conditions the promoter is active ( Fig. 6G ).
Cdk9 has a role in adipocyte biology
Besides its participation in adipocyte differentiation PPARγ also plays a major role in adipocyte biology through regulation of genes implicated mainly in lipogenesis. Since cdk9 modulates PPARγ activity we asked whether cdk9 could also participate in these processes. First, we analysed the mRNA expression of lipogenic genes such as aP2, lipoprotein lipase (LPL), stearoyl CoA desaturase (SCD1), and fatty acid synthase (FAS). DRB treatment of 3T3-L1 adipocytes resulted in the inhibition of the expression of aP2, LPL, SCD1, and FAS ( Fig. 7A ), whereas no changes in the expression of genes implicated in lipolysis were observed (data not shown). These results suggested that similar to PPARγ, cdk9 could also be implicated in lipogenesis. Interestingly, expression of cdk9 was strongly increased in adipose tissue of mice fed a high fat diet ( Fig. 7B ). Furthermore, genetically obese db/db mice expressed high levels of cdk9 mRNA in adipose tissue compared to control non-obese mice (Fig. 7C ).
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Discussion
General transcription is regulated by the activity of RNA pol II. The P-TEFb complex plays a crucial role in the control of transcriptional elongation through phosphorylation of CTD of RNA pol II. Increasing evidence suggest that P-TEFb also participates in the transcriptional regulation of specific genes through recruitment to specific promoters by particular transcription factors. Such is the case for c-Myc (20),
NFκB (8), AR (9), and MyoD (5) . As a result of the regulation of specific genes, P-TEFb coordinates cellular processes ranging from apoptosis, monocyte differentiation, or myogenesis (reviewed in (21)). In this study, we analysed the participation of cdk9 in adipocyte differentiation and we found that cdk9 was required for adipogenesis. This is supported by several observations. First, expression of cdk9p55 is highly upregulated during adipocyte differentiation ( Fig. 1 ). Second, cdk9 activity is increased during adipogenesis ( Fig. 1 ). Third, overexpression of cdk9 results in increased adipogenesis, whereas inhibition of cdk9 impairs the adipogenic potential of the cells (Fig. 2-3 ). Finally, cdk9 increases PPARγ activity through direct interaction with PPARγ on the promoters of PPARγ target genes (Fig. 4) . The central role of PPARγ in adipose tissue differentiation and biology has been largely demonstrated. Consequently, any factor modulating PPARγ activity, and such is the case for cdk9, will have a major impact on adipocyte differentiation.
A similar scenario has been observed for the transcription factor MyoD. In this case, cdk9 phosphorylates MyoD and increases its transcriptional activity (5) . Similarly, PPARγ is also phosphorylated by the P-TEFb complex, which may account for the observed effects of cdk9 on PPARγ activity. Interestingly, PPARγ is phosphorylated at S112, exactly the same residue previously reported to be phosphorylated by MAPK and cdk7 (22) (23) (24) . The effects of PPARγ phosphorylation on PPARγ activity are so far inconsistent. MAPK phosphorylation of PPARγ has been reported to inhibit its activity (22, 23) , whereas phosphorylation by cdk7 has been shown to be required for PPARγ-mediated transactivation (24) . Our results are in agreement with this last study, and show that PPARγ phosphorylation by cdk9 results in PPARγ activation. Three different observations support this hypothesis. First, cdk9 mediates PPARγ activation in transient transfection assays (Fig. 4) . Second, PPARγ phosphorylation correlates with PPARγ 11 maximal activity in transactivation of target genes (Fig. 6 ). Finally, phosphorylated PPARγ is complexed to the active promoters of target genes together with cdk9 ( Fig. 6 ). How can phosphorylation of PPARγ at the same residue by different kinases result in either activation or repression of this transcription factor?
One possible explanation is cofactor recruitment. The interaction of PPARγ with either kinase could modulate the interaction of PPARγ with different cofactors. In the case of MAPK, the interaction could result in the recruitment of corepressors, whereas for cdk7 and cdk9, the interaction could result in the recruitment of coactivators and the general transcriptional machinery. Coactivators recruitment is likely not the case, since we did not observe any difference in cofactors recruitment to PPARγ in the absence or presence of cdk9 (data not shown). Alternatively, phosphorylation of PPARγ might be required for optimal activation. The effects observed upon MAPK inactivation on PPARγ could be indirect, such as replacement of PPARγ by a more potent transcription factor. Unfortunately no data is available on the presence of PPARγ on the promoters of its target genes when MAPK inhibitors are used. Since phosphorylation of PPARγ coincides with RNA pol II CTD phosphorylation, we believe that PPARγ could tether the P-TEFb complex to the RNA pol II complex, facilitating phosphorylation and therefore elongation of the transcription of its target gene. This is the mechanism that has been suggested to explain the positive effects on the transcription of AR (9), AhR (10), or NFκB (8) mediated by the interaction of cdk9 with these transcription factors. In contrast to this, another mechanism of regulation of pTEFb activity was recently described for the glucocorticoid receptor (GR). In this scenario GR inhibits pTEFb activity by competing for binding to RelA and p50 complex on the promoter of the IL-8 gene, resulting in the repression of this gene (25) .
The analysis of the expression of cdk9 during adipocyte differentiation showed that the recently identified cdk9 isoform, p55, which is transcribed from an alternative promoter (2) increases during differentiation.
This pattern of expression of p55cdk9 is suggestive of being a PPARγ target gene. Interestingly, we have identified a highly conserved PPAR−responsive element in the promoter of p55cdk9 (data not shown).
Regulation of cdk9 expression by PPARγ would result in a positive feed-back loop increasing the availability of cdk9 to activate PPARγ-mediated transcription.
12
During adipocyte differentiation, which is a highly coordinated process, only a subset of genes are activated resulting in the specific adipocyte phenotype (reviewed in (15) ). This selective transcriptional activation supports the idea that the effects of cdk9 are rather gene specific than an effect on general transcription in the context of adipogenesis, and likely in other differentiation processes. Most interesting is the fact that cdk9 could participate in adipose tissue biology in addition to adipocyte differentiation. In differentiated adipocytes cdk9 inactivation results in the inhibition of the expression of genes implicated in lipogenesis, which is consistent with the increased expression of cdk9 that we found in mouse models of obesity. This may have important therapeutical implications, for instance in the context of obesity.
Studies on the effects of specific cdk9 inhibitors in adiposity in mice are currently ongoing.
In summary, in this study we provide evidence that the nuclear receptor PPARγ uses the P-TEFb complex to stimulate the transcription of its target genes to drive adipogenesis. 
Materials and methods
Materials
RNA isolation, Reverse transcription and Real Time PCR
RNA was purified using an RNeasy Mini Kit of Qiagen (Hilden, Germany). Reverse transcription of total RNA was performed at 37°C using the M-MLV reverse transcriptase (Invitrogen SARL, France) and random hexanucleotides primers (Promega, Madison, WI), followed by a 15 min inactivation at 70°C.
Quantitative PCR was carried out by Real Time PCR using a LightCycler and the DNA double strand hr. Twenty-four hr following transfections, G418 or puromycin (Invitrogen SARL, France) was added at a final concentration of 1mg/ml or 2.5 µg/ml respectively. The medium plus G418 or puromycin was replaced 3 times/week until no surviving cells were observed. 
Protein expression assays
Coimmunoprecipitation and chromatin immunoprecipitation (ChIP) assays
For co-immunoprecipitation assays whole cell extracts were precleared with protein A-agarose beads (Roche) during 30 minutes at room temperature, an aliquote of the precleared lysates was saved as input.
Extracts were then centrifuged (5 minutes at 3000rpm) and supernatants were immunoprecipitated with the indicated specific antibodies overnight at 4°C, rabbit IgGs (Sigma, St-Louis, MO) were used as negative control (mock). Immunoprecipitates were then washed twice with IP buffer (150mM NaCl, 1%
NP40, 50mM Tris/HCl pH8 and protease inhibitor cocktail) and three times with washing buffer (0,25M KCl in PBS) and subjected to SDS-PAGE electrophoresis. Chromatin immunoprecipitation assays were performed as described previously (31). Briefly, proteins were formaldehyde cross-linked to DNA in confluent 3T3-L1 preadipocytes before induction of differentiation or in cells induced with differentiation medium for 7 days. Proteins were then immunoprecipitated using the indicated antibodies, rabbit IgGs or beads were used as mock, DNA was extracted from the immunoprecipitates and PCR amplification was performed using promoter-specific oligonucleotide primers.
Pull-down assays
In vitro translation of pCMV-cdk9 was performed with 35 S-methionine (Perkin Elmer, Boston, MA) in a TNT-coupled transcription-translation system, as described by the manufacturer (Promega, Madison, WI).
GST fusion or GST alone were expressed in Escherichia Coli, and purified on glutathione-sepharose-4B beads (Amersham Biosciences, Uppsala, Sweden). For in vitro binding GST, GST-PPARγ AB, GST-PPARγ DE and GST-PPARγ deletion mutants were incubated with the labeled protein in 1 ml binding 16 buffer containing 300mM NaCl, 0.5% Triton-X-100, 50mM Tris pH8, and 2mM EDTA at room temperature for 1 hr. Beads were washed five times with the same buffer. The proteins were visualized by autoradiography after SDS-PAGE electrophoresis.
Kinase assays
Immunoprecipitated cdk9 from 3T3-L1 cells at different stages of differentiation was used as kinase.
Immunoprecipitates were washed once with kinase buffer (25mM Tris/HCl pH7.5, 150mM NaCl, 10mM gels were then dried in a gel dryer for 1h at 80 o C and exposed to an X-ray film. 
